Drugs / Chlorprocaine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06302257 | Mar 2024 → Mar 2028 expected | — | Hadassah Medical Organization | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07601750 Comparator | Jan 2025 → Dec 2028 expected | — | Baylor Research Institute | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chlorprocaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07601750 ↗ |
| Action | Inhibit | “activation of TRPV1 channels together with anesthetic doses of chloroprocaine leads to enhanced inhibition of sodium currents in nociceptive neurons in vitro” NCT06302257 ↗ |